Education
About Us
Working with TipRanks
Follow Us
Elan Corp. (JP:6099)
:6099
Top Page
Elan Corp.
(Frankfurt:6099)
74Outperform
Elan Corp. (6099) vs. S&P 500 (SPY)
Market Cap
€43.53B
Dividend Yield1.95%
Average Volume (3M)96.27K
Price to Earnings (P/E)18.5
Beta (1Y)0.67
Revenue Growth14.70%
EPS Growth-6.51%
CountryJP
Employees566
SectorHealthcare
Sector Strength64
IndustryHealthcare Providers & Services
Share Statistics
EPS (TTM)8.64
Shares Outstanding60,600,000
10 Day Avg. Volume128,790
30 Day Avg. Volume96,266
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Elan Corp. Business Overview & Revenue Model
Company DescriptionELAN Corp operates in the medical industry. The company provides "CS set" system for renting personal items, clothing and towels.
How the Company Makes Money
Elan Corp. Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 47.51B | 41.43B | 36.26B | 31.64B | 26.06B | Gross Profit |
| 10.72B | 9.75B | 9.03B | 7.88B | 6.56B | EBIT |
| 3.58B | 3.67B | 3.39B | 2.80B | 2.07B | EBITDA |
| 4.49B | 3.85B | 3.53B | 2.92B | 2.27B | Net Income Common Stockholders |
| 2.35B | 2.52B | 2.08B | 1.91B | 1.45B |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 6.85B | 5.49B | 6.04B | 5.63B | 4.50B | Total Assets |
| 21.61B | 18.99B | 16.07B | 13.95B | 11.69B | Total Debt |
| 76.62M | 0.00 | 0.00 | 0.00 | 0.00 | Net Debt |
| -6.75B | -5.49B | -6.04B | -5.63B | -4.50B | Total Liabilities |
| 9.10B | 8.18B | 7.08B | 6.46B | 5.50B | Stockholders Equity |
| 12.50B | 10.81B | 8.99B | 7.48B | 6.18B |
| Cash Flow | Free Cash Flow | |||
| 3.62B | 1.59B | 1.23B | 2.03B | 1.86B | Operating Cash Flow |
| 4.50B | 1.78B | 1.58B | 2.11B | 1.95B | Investing Cash Flow |
| -2.23B | -1.66B | -624.51M | -357.68M | -648.33M | Financing Cash Flow |
| -849.53M | -667.09M | -552.96M | -614.15M | -273.82M |
Elan Corp. Technical Analysis
Negative
719.00
Price Trends
742.42
Negative
732.78
Negative
794.50
Negative
Market Momentum
-7.49
Negative
50.86
Neutral
86.83
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:6099, the sentiment is Negative. The current price of 719 is above the 20-day moving average (MA) of 709.55, below the 50-day MA of 742.42, and below the 200-day MA of 794.50, indicating a neutral trend. The MACD of -7.49 indicates Negative momentum. The RSI at 50.86 is Neutral, neither overbought nor oversold. The STOCH value of 86.83 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:6099.
Elan Corp. Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | $815.54B | 11.03 | 9.06% | 4.26% | -2.16% | -40.39% | |
79 Outperform | $10.34T | 26.70 | 21.61% | 1.41% | 5.33% | 18.98% | |
74 Outperform | €43.53B | 18.49 | 19.67% | 1.95% | 14.70% | -6.51% | |
72 Outperform | $5.83T | 24.06 | 14.97% | 1.80% | 19.46% | 32.98% | |
68 Neutral | $6.68T | 31.93 | 2.87% | 4.37% | 9.83% | 15.49% | |
62 Neutral | $2.29T | 49.09 | -3.80% | 5.53% | 21.01% | -12669.88% | |
51 Neutral | $5.20B | 3.18 | -40.80% | 2.96% | 17.66% | 1.94% |
* Healthcare Sector Average
Performance Comparison
JP:6099
Elan Corp.
725.00
-161.10
-18.18%
JP:4503
Astellas Pharma
1,349.50
-52.48
-3.74%
JP:4519
Chugai Pharmaceutical Co
8,194.00
3,079.34
60.21%
JP:4528
ONO Pharmaceutical Co
1,696.00
-499.24
-22.74%
JP:4502
Takeda Pharmaceutical Co
4,300.00
347.16
8.78%
JP:4568
Daiichi Sankyo Company
3,233.00
-1,429.27
-30.66%
Elan Corp. Corporate Events
Elan Corporation Releases 2024 Annual Securities Report
Mar 24, 2025
Elan Corporation has released its annual securities report for the fiscal year 2024, detailing its financial performance and strategic initiatives. The report outlines the company’s management policies, sustainability efforts, and business risks, providing stakeholders with insights into its operational strategies and market positioning.
ELAN Corporation Reports Fiscal Year 2024 Financial Results
Feb 10, 2025
Elan Corporation reported its consolidated financial results for the fiscal year ending December 31, 2024. The company experienced a 14.7% increase in net sales compared to the previous year, but saw decreases in operating, ordinary, and attributable profits by 2.4%, 3.7%, and 6.5% respectively. Despite these declines, Elan’s total assets grew significantly, with a notable improvement in cash flows from operating activities. The company also announced a forecasted increase in annual dividends per share for 2025, indicating positive expectations for future growth.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.